Japanese Yen: Consolidation before potential push to 160.55 against US Dollar – UOB
United Overseas Bank’s (UOB) Quek Ser Leang and Lee Sue Ann report that USD/JPY has pulled back from 160.20, with intraday price action expected to stay between 159.50 and 160.15 as upward pressure eases. Over the next 1–3 weeks, they maintain a slightly positive stance, seeing scope for the pair to edge higher toward 160.55 as long as support at 159.20 holds. Longer-term, the uptrend remains intact above the 21-day EMA.
Dollar-Yen holds firm within tight band
"24-HOUR VIEW: Subsequent to last Friday’s sharp rise to 160.04, we highlighted yesterday, when USD was at 160.00, that “the rapid rise appears overdone, and USD is unlikely to rise much further.” We expected USD to “consolidate at these higher levels between 159.65 and 160.25.” USD did not quite consolidate as after rising to 160.20, it dropped sharply to 159.45 and then rebounded to close at 159.73 (-0.19%). Upward pressure has eased, but there has been no clear increase in downward momentum. Today, we expect USD to rangetrade, most likely between 159.50 and 160.15."
"1-3 WEEKS VIEW: We turned slightly positive on USD yesterday (31 Aug, spot at 160.00). We indicated that “upward momentum has increased, albeit only slightly.” We also indicated that “as long as USD holds above 159.20 (‘strong support’ level), it could edge higher toward 160.55.” Our view remains unchanged."
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
The second wave of energy price increases is looming! European Central Bank’s Lane warns: eurozone inflation will be higher and more persistent
Philip Lane, Chief Economist of the European Central Bank, stated that a new round of high energy prices means inflation in the eurozone will remain elevated for longer than the ECB initially anticipated.
Bitcoin Trades Around $86K as FOMO Hits Highest Level Since 2024

siRNA rising star ADARx (ADRX.US) launches $350 millions IPO, AbbVie subscribes to 4.9% of shares with a maximum investment of $100 millions
ADARx plans to raise $350 millions and list on Nasdaq. AbbVie will invest up to $100 millions to acquire a 4.9% stake, with a median valuation of $1.8 billions.
Roche (RHHBY.US) weight loss injection shows positive mid-term trial results: average weight loss of 15.5% over 48 weeks, blood sugar levels drop by 2.65%.
The experimental weight-loss injection enicepatide simultaneously lowered blood sugar and body weight in overweight or obese patients with type 2 diabetes during a mid-stage clinical trial.
